Skip to main content
. Author manuscript; available in PMC: 2020 Sep 20.
Published in final edited form as: Curr Cancer Drug Targets. 2020;20(4):253–270. doi: 10.2174/1568009619666191202101330

Fig. 6.

Fig. 6.

Resorcinol-containing Hsp90 inhibitors – All inhibitors in this class contain a resorcinol moiety. A-C) Luminespib, ganetespib, and onalespib add two substituents to the resorcinol ring at ortho-positions to the hydroxyl groups; one is an isopropanol moiety and the other is unique to each compound. D) KW-2478 adds three substituents to the resorcinol moiety – two ortho and one meta to the hydroxyl groups.